Bank of New York Mellon
AMAM

Bank of New York Mellon’s Ambrx Biopharma Inc AMAM Stock Holding History

Bank of New York Mellon’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-47,433
Closed -$545K – 4407
2023
Q3 		$545K Buy
+47,433
New +$646K ﹤0.01% 3499

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon's AMAM Position: Q4 2023 in Review

Bank of New York Mellon sold out of Ambrx Biopharma Inc (AMAM) in Q4 2023, closing a stake of 47,433 shares — an estimated $545K sold.

Bank of New York Mellon first reported a position in AMAM in Q3 2023 and held it in 1 quarter. The position peaked at $545K in Q3 2023. 68 funds tracked by Wall St. Rank hold AMAM as of Q4 2023.

  • Bank of New York Mellon reported no remaining Ambrx Biopharma Inc position as of Q4 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 47,433 Ambrx Biopharma Inc shares in Q4 2023, an estimated $545K.
  • Bank of New York Mellon first reported a position in Ambrx Biopharma Inc in Q3 2023 and held it in 1 quarter.
  • Bank of New York Mellon's Ambrx Biopharma Inc position peaked at $545K in Q3 2023.
  • 68 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2023.

Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.